PRODUCT PIPELINE
BioXcel Therapeutics’ two most advanced clinical development programs are BXCL501 and BXCL701. BXCL501 is a proprietary, sublingual film formulation of dexmedetomidine being developed for at-home use for the acute treatment of agitation in bipolar and schizophrenia patients, for the acute treatment of agitation associated with Alzheimer’s disease, and as an adjunctive treatment for Major Depressive Disorder. BXCL501 has been granted Breakthrough Therapy and Fast Track designation for the acute treatment of agitation associated with dementia. BXCL701 is an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. BXCL501 has been granted Breakthrough Therapy and Fast Track designation for the acute treatment of agitation associated with dementia.
Our Clinical Pipeline
The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established
*Includes intermittent chronic agitation
**Regulatory path to be determined; device + drug combination to be evaluated after further evaluation of predictive algorithm
Pipeline as of Sept. 12, 2022
BXCL501
BXCL501 is our most advanced neuroscience clinical program. BXCL501 is a proprietary, sublingual film formulation of dexmedetomidine, a selective alpha-2 receptor agonist. It is being investigated for at-home use for the acute treatment of agitation in bipolar and schizophrenia patients, for agitation in Alzheimer’s disease, and as an adjunctive treatment for major depressive disorder.
BXCL501 has received Breakthrough Therapy and Fast Track designation for the acute treatment of agitation associated with dementia. In 2021, the Company announced positive topline results from the TRANQUILITY Phase 1b/2 trial for the acute treatment of agitation associated with dementia, including Alzheimer’s disease. Following discussions with the FDA in Q4 2021, we initiated our pivotal phase 3 program of BXCL501 for acute treatment of agitation in patients with Alzheimer’s disease. The Company has also submitted an Investigational New Drug (IND) application to evaluate BXCL501 as adjunctive treatment for major depressive disorder (MDD).
BXCL701
BXCL701 (talabostat) is an investigational, oral small molecule inhibitor of dipeptidyl peptidases (DPP)—primarily DPP 8/9 and DPP 4—which triggers inflammasome to alert and prime immune cells, leading to the induction of IL-18 and IL-1ß, bridging innate and adaptive immunity. The Company is conducting a Phase 1b/2 trial of BXCL701 in combination with KEYTRUDA® (pembrolizumab) for the treatment of small cell neuroendocrine prostate cancer (SCNC), an aggressive variant of metastatic castration-resistant prostate cancer.
